Skip to content

Quantitative Thresholds on 18F-DCFPyL PET for Determining Malignancy in Prostate Cancer with Pathologic Correlation.

Sep 2026 · Journal of Nuclear Medicine · 0 citations · 29 references
Medicine

Abstract

In this article, we assess histologically validated quantitative parameters on 18F-piflufolastat (18F-DCFPyL) prostate-specific membrane antigen (PSMA) PET and identify thresholds for differentiating malignant prostate cancer from benign tissue. Methods: In this multicenter retrospective study, men with prostate cancer who underwent 18F-DCFPyL PET/CT followed by surgery or biopsy at 4 institutions were included. Histopathology reports and CT-guided biopsy images were anatomically matched to PET/CT, and corresponding regions of interest were delineated. Univariable associations between lesion malignancy and PET parameters (SUVmax/mean, total lesion uptake (TLU), tumor volume (TV), ratios to blood, liver, and spleen) were tested using likelihood ratio tests. Multivariable models incorporating PET and clinical variables were also evaluated. Analyses were performed for all lesions combined and separately for prostate and metastatic lesions. Results: In total, 305 men with 476 PET regions of interest matched to histologic specimens were analyzed. Across all lesions, malignancy was associated with all PSMA PET parameters (P = 0.011 for TV; P < 0.001 for all other metrics). Similar associations were observed in metastatic lesions (P = 0.001 for TV; P < 0.001 for all other metrics). In prostate lesions, malignancy was associated with all PET parameters except TV (P = 0.970 for TV; P < 0.001 for all other metrics). Among all evaluated metrics, SUVmax to blood-pool ratio showed the highest discriminatory performance across all lesions, prostate lesions, and metastatic lesions, with thresholds ranging from 2.86 to 2.97, sensitivities from 0.841 to 0.950, and specificities from 0.788 to 0.911. Ratios of TLU to blood-pool, liver, and spleen also performed well. SUVmax, SUVmean, and TLU yielded good sensitivity across cohorts, although specificity was lower in some subgroups. For prostate lesions, the SUVmax threshold of 5.43 yielded a sensitivity of 0.843 and a specificity of 0.927. Multivariable models combining PET parameters, particularly blood-pool and liver-referenced metrics, with clinical variables further improved discrimination between malignant and benign lesions. Conclusion: SUVmax-to-blood and TLU-to-blood cutoffs can distinguish malignant prostate cancer from benign tissue and may support clinical decision-making, including biopsy selection. Larger studies are required for further confirmation.

View source

Similar papers

Open access Oct 2026

Diagnostic accuracy of 18F-PSMA-1007 PET/CT and bone scintigraphy for detecting bone metastases in prostate cancer.

OBJECTIVE The performance of 18F-labeled prostate-specific membrane antigen (18F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) and bone scintigraphy (BS) for detecting bone metastases in prostate cancer patients was compared. MATERIALS AND METHODS One hundred prostate cancer patients (initial s...

Kazuhiro Kitajima, Sadahiro Naka, Koji Hatano et al. · 0 citations
Review Open access Sep 2026

miPSMA Score in 68 Ga-PSMA PET-CT: An Institutional Review from Pakistan

Abstract Objectives Prostate cancer is the second most common cancer in men and a leading cause of cancer-related death worldwide. Accurate staging is essential for effective treatment. The use of gallium-68 ( 68 Ga)-prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT), a...

S. M. Gill, Aamna Hassan, H. Bashir et al. · 0 citations
Review Open access Aug 2026

An Apparent Diffusion Coefficient-Based Radiomics Tool for Clinically Significant Prostate Cancer Detection in PI-RADS 3 Lesions: A Multicenter Study.

The apparent diffusion coefficient-based radiomics model effectively detected csPCa in PI-RADS 3 lesions in the training set and demonstrated moderate performance in the external validation set.

G. Gao, Ke-Xin Wang, Xiao-Ying Wang et al. · 0 citations
Open access Aug 2026

The Role of 68Ga-FAPi PET/CT in Staging and Restaging of Breast Cancer Subtypes with Limited 18F-FDG Uptake

68Ga-FAPi PET/CT provides a significant advantage for staging and restaging breast cancer—especially lobular carcinoma and other low 18F-FDG-avid subtypes—supporting its potential role in clinical decision-making and treatment planning.

Gamze Beydağı, N. Selcuk, Kaan Akçay et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.